skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease

Original Research

(2853) Views  (852) Full article downloads

Authors: Heather E Vezina, Richard C Brundage, Thomas E Nevins, et al

Published Date December 2009 Volume 2010:2 Pages 1 - 7
DOI: http://dx.doi.org/10.2147/CPAA.S8341

Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,3

1Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA

Abstract: Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and valganciclovir dosing strategies in children are highly variable. Our objective was to characterize the pharmacokinetics of ganciclovir in the plasma of pediatric kidney and liver transplant patients taking valganciclovir for EBV prophylaxis. Virologic response was also evaluated. Ganciclovir was measured by liquid chromatography/ultraviolet detection. EBV DNA was quantified by TaqMan® polymerase chain reaction. NONMEM® VI was used for data analysis. Ganciclovir plasma profiles were consistent with a one-compartment model. Final model estimates of apparent oral clearance (L/h), apparent volume of distribution (L), and absorption rate constant were 7.33, 35.1, and 0.85, respectively. There was evidence of lower bioavailability in children younger than three years. All eight subjects achieved ganciclovir plasma concentrations above reported in vitro concentrations needed to inhibit EBV replication by 50%. However, four subjects had detectable EBV DNA with a median (range) of 18,300 (4,400 to 54,900) copies/mL of whole blood. These findings support the need for further studies of the clinical pharmacology and efficacy of valganciclovir for EBV prophylaxis.

Keywords: valganciclovir, ganciclovir, pharmacokinetics, Epstein–Barr virus, pediatrics, solid organ transplantation








Readers of this article also read:

Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease
Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent
Nanoparticle-labeled stem cells: a novel therapeutic vehicle
Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician
Pharmacologic agents for smoking cessation: A clinical review
Adverse drug effects in hospitalized elderly: Data from the Healthcare Cost and Utilization Project
A case of cephalothin-associated urolithiasis
Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Human normal immunoglobulin in the treatment of primary immunodeficiency diseases
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University